We support one of the strongest combinations of research, clinical and trials expertise in sarcoma anywhere in the world.

The combined clinical and research expertise in LMS at the Marsden and ICR, together with the archive of LMS tissue samples and patient data at the Royal Marsden Hospital, provide a unique and rare opportunity to achieve something remarkable.

We plan to help make ICR and The Royal Marsden one of the global centres of expertise for LMS.

Breakthroughs in cancer treatment of major cancer types using immunotherapy and targeted medicines have not yet been realised in LMS. 

Our objective is to help change that.

We support LMS research and studies that: 

  • Use artificial intelligence and pathology expertise to mine the extensive LMS tissue samples and data held at the Royal Marsden Hospital

  • Discover new bio-markers and define LMS sub-types

  • Characterise disease pathways using transcriptomic and proteomic techniques

  • Identify new therapeutic targets

  • Deliver the basis for precision-based medicine for LMS

We intend that our funding and support model can be replicated by others to develop precision-based therapy for other rare cancers.

LMSRF plans also to work closely with a separate, newly-established charity: LMS Research UK. Set up in 2024 as a sister charity to a LMSDR (a small US charity with no administration costs which is in close communication with US-based LMS clinical and research teams and which acts as an excellent source and exchange of information for LMS patients globally, as well as providing small research grants totalling $150k p.a.), LMS Research UK plans to bring together the research community in the UK as a network and to seek to support fundamental research in LMS.  For LMSRF, the improved networking of the disparate LMS research community is welcomed: it will enable us to share research findings and to include UK-wide research expertise in the work which we support.  LMS Research UK may also uncover additional key research initiatives for LMRSF to support.